Alimera Sciences Inc. (ALIM)
Symbol Info
Listed Symbol ALIM
Name Alimera Sciences Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $46,970,000
Latest Fiscal EPS $0.21
Price Info
21 Day Moving Average $0.4659
21 Day EMA $0.448880
50 Day Moving Average $0.4656
50 Day EMA $0.509780
200 Day EMA $0.759600
200 Day Moving Average 0.828610
52 Week High $1.21
52 Week Low $0.32
52 Week Change $-58.145897
Alpha -0.039333
Beta 2.0370
Standard Deviation 0.193809
R2 0.130411
Periods 60
Share Information
10 Day Average Volume 394,610
20 Day Average Volume 436,998
30 Day Average Volume 405,485
50 Day Average Volume 282,349
Outstanding Shares 71,009,400
Float Shares 69,832,725
Percent Float 98.34%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 64
Institute Holdings Date 2019-09-30
Institute Bought Previous 3 Months 200,600
Institute Holdings Percent 57.600000
Institute Sold Previous 3 Months 1,348,708
Insider Holdings Date 2019-08-31
Insider Bought Previous 3 Months 7
Insider Holdings Percent 1.70%
Insider Sold Previous 3 Months -
Insiders Shares Owned 1,176,675
Price Change
7 Day Price Change $-0.01353
7 Day Percent Change -3.27%
21 Day Price Change $-0.1
21 Day Percent Change -20.00%
30 Day Price Change $0.0501000
30 Day Percent Change 14.32%
Month To Date Price Change $-0.1663
Month To Date Percent -29.37%
90 Day Price Change $-0.48
90 Day Percent Change -54.55%
Quarter To Date $-0.1663
Quarter To Date Percent -29.37%
180 Day Price Change $-0.65
180 Day Percent Change -61.90%
200 Day Price Change $-0.69
200 Day Percent Change -63.30%
Year To Date $-0.3181
Year To Date Percent -44.30%
Profile
Description Alimera Sciences Inc is a pharmaceutical company. It specializes in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration, and retinal vein occlusion. The product portfolio of the company includes ILUVIEN, which is developed to treat diabetic macular edema. In addition, to the activities related to the development of ILUVIEN, the group is also researching the safety and effectiveness of NADPH (Nicotinamide Adenine Dinucleotide Phosphate) oxidase inhibitors. Geographically it operates through the region of US and also it has its presence in the international market.
Details
Issue Type CS
Market Cap $28,403,760
Sec Type EQS
Auditor Grant Thornton LLP
Total Shares Outstanding 71,009,400
CEO Richard S. Eiswirth
Employees 124
Last Audit UE
Classification
CIK 0001267602
Industry Drug Manufacturers
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 6120 Windward Parkway
Suite 290
Alpharetta, GA 30005
Website http://www.alimerasciences.com
Facisimile +1 678 990-5744
Telephone +1 678 990-5740
Email John.Mills@ICRINC.com
Key Ratios
Profitability
EBIT Margin -14.3
EBITDA Margin -9.1
Pre-Tax Profit Margin -150.4
Profit Margin Cont -23.29
Gross Margin 89.20
Profit Margin TOT -23.29
Income Statements
Revenue $38,859,000
Revenue Per Share $0.5472
Revenue 3 Years $10.33
Revenue 5 Years $39.70
Valuation Measures
PE Ratio 1.60
Enterprise Value $97,106,623
Price To Sales 0.730944
Price To Free Cash -557.9
PE High Last 5 Years -
Price To Book 13.0
Price To Cash Flow -
PE Low Last 5 Years -
Price To Tangible Book -0.6
Financial Strength
Total Debt To Equity -
Int Coverage -1.5
Current Ratio 2.7
Leverage Ratio -1.6
Quick Ratio 2.2
Long Term Debt To Capital -
Assets
Receivables Turnover 1.2
Invoice Turnover 2.80
Assets Turnover 0.30
Management Effectiveness
Return Assets 49.17
Return On Equity -53.1
Return On Capital -
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
ALIM
Alimera Sc..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.